Weinbroum Avi A
Post-Anesthesia Care Unit and Animal Research Laboratory, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Israel.
J Trauma. 2006 Jun;60(6):1290-6. doi: 10.1097/01.ta.0000220382.91449.4a.
Mannitol (MN) and N- acetylcysteine (NAC) are partially successful in preventing lung reperfusion injury after liver ischemia reperfusion (IR). Their concomitant administration might enhance the individual effects of each.
Rat isolated livers were perfused with Krebs-Henseleit solution (controls) or made globally ischemic (IR) for 2 hours. Separately isolated lungs were paired with livers and each pair was reperfused in-series for 15 minutes. During reperfusion, eight groups were treated with Krebs containing two low and two high doses of MN and/or NAC; one group received no treatment.
The tested lung parameters were unchanged in all control groups. Pulmonary perfusion or ventilatory pressures, weight gain and bronchoalveolar lavage volume increased by 30 to 70% of baseline in the nontreated IR-paired lungs and in the only IR-MN 0.44- and the IR-NAC 0.25 mmol (weight/body weight) treated lungs but remained preserved by the two higher monotherapies (MN 0.55 mmol and NAC 0.37 mmol) and by the four bitherapies. The reduced glutathione content in all lung tissue subgroups treated by the bitherapies was higher by 63 to 124% of the corresponding monotherapy values. Xanthine oxidase activity in the bitherapies-treated IR-lungs decreased 1.5 to twofold compared with the corresponding monotherapies.
Co-administration of MN and NAC augments the amount of lung protection afforded by each drug individually and enhances their antioxidant potentials.
甘露醇(MN)和N - 乙酰半胱氨酸(NAC)在预防肝缺血再灌注(IR)后的肺再灌注损伤方面取得了部分成功。它们联合使用可能会增强各自的单独效果。
用Krebs - Henseleit溶液灌注大鼠离体肝脏(对照组)或使其整体缺血(IR)2小时。将单独分离的肺与肝脏配对,每对进行串联再灌注15分钟。在再灌注期间,八组接受含有两种低剂量和两种高剂量MN和/或NAC的Krebs溶液处理;一组未接受治疗。
所有对照组的测试肺参数均未改变。在未治疗的IR配对肺、仅接受IR - MN 0.44 mmol和IR - NAC 0.25 mmol(体重/体重)治疗的肺中,肺灌注或通气压力、体重增加和支气管肺泡灌洗量增加了基线的30%至70%,但两种较高剂量的单一疗法(MN 0.55 mmol和NAC 0.37 mmol)以及四种联合疗法使其保持在正常水平。联合疗法治疗的所有肺组织亚组中的还原型谷胱甘肽含量比相应单一疗法值高63%至124%。联合疗法治疗的IR肺中的黄嘌呤氧化酶活性与相应单一疗法相比降低了1.5至两倍。
MN和NAC联合使用增强了每种药物单独提供的肺保护量,并增强了它们的抗氧化潜力。